Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

YESINTEK - Health Canada Drug Approval Details

Approvals/Health Canada/YESINTEK

Authorized

STANDARD

YESINTEK

Biosimilar Collaborations Ireland Ltd.🇨🇦 Health Canada

Approval Date: Apr 6, 2026
Approval ID: dab3deb1e5bc5601
Company: Biosimilar Collaborations Ireland Ltd.
Type: Standard

Approval Details

Approval Id: dab3deb1e5bc5601
Drug Approval Canada Name: YESINTEK
Product Name: YESINTEK
Status: Marketed
Status Date: 2025-10-24
Original Market Date: 2025-10-24
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: PRESCRIPTION , SCHEDULE D
Ahfs: 90:24.20.92
Atc Original: L04AC05 USTEKINUMAB
Aig Number: 0152506001
Company Name: Biosimilar Collaborations Ireland Ltd.
Company Address: UNIT 35/36 Grange Parade, Baldoyle Industrial Estate, Dublin 13 Dublin -- Ireland D13R20R
Company Detail Path: /organization/6ede2f8e042001c5/biosimilar-collaborations-ireland-ltd

Company Information

Pharmaceutical Company Name: Biosimilar Collaborations Ireland Ltd.
Country Name: Ireland

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Apr 6, 2026

Approval ID

dab3deb1e5bc5601

Type

Standard

Back to Health Canada Approvals